ISSN 1662-4009 (online)

ey0018.9-8 | Genetic susceptibility to treatment-related gonadotoxicity | ESPEYB18

9.8. Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function

ALF van der Kooi , M van Dijk , L Broer , MH van den Berg , JSE Laven , FE van Leeuwen , CB Lambalk , A Overbeek , JJ Loonen , HJ van der Pal , WJ Tissing , B Versluys , D Bresters , CCM Beerendonk , CR Ronckers , M van der Heiden-van der Loo , GL Kaspers , ACH de Vries , LL Robison , MM Hudson , W Chemaitilly , J Byrne , C Berger , E Clemens , U Dirksen , J Falck Winther , SD Fossa , D Grabow , R Haupt , M Kaiser , T Kepak , J Kruseova , D Modan-Moses , SMF Pluijm , C Spix , O Zolk , P Kaatsch , JH Krijthe , LC Kremer , Y Yasui , RJ Brooke , AG Uitterlinden , M van den Heuvel-Eibrink , E Mvan Dulmen-den Broeder

Hum Reprod. 2021; 36: 1120–1133. https://pubmed.ncbi.nlm.nih.gov/33582778/This multi-centre retrospective cohort study identifies that common genetic variants in DNA repair genes modify the damage induced by alkylating agents on ovarian function, as assessed by low AMH levels.Alkylating agents are known to induce apoptosis of cancer cells by damaging DNA replicat...